Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma
BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC). Our previous study suggested that epidermal growth factor receptor inhibitor erlotinib which acts upstream of these...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-07-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S147655861630015X |
id |
doaj-0293d56686f54accaad482542a29b03c |
---|---|
record_format |
Article |
spelling |
doaj-0293d56686f54accaad482542a29b03c2020-11-24T23:48:49ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022016-07-0118742543510.1016/j.neo.2016.06.001Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal AdenocarcinomaMatthew H. Wong0Aiqun Xue1Robert C. Baxter2Nick Pavlakis3Ross C. Smith4Cancer Surgery Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, AustraliaCancer Surgery Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, AustraliaHormones and Cancer, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, AustraliaDepartment of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, AustraliaCancer Surgery Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, AustraliaBACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC). Our previous study suggested that epidermal growth factor receptor inhibitor erlotinib which acts upstream of these pathways acts synergistically with PI3K inhibitors in PDAC. Horizontal combined blockade upstream and downstream of these two pathways is therefore explored. METHODS: Erlotinib paired with PI3K inhibitor (BYL719) was tested against erlotinib plus dual PI3K/mTOR inhibitor BEZ-235, and MEK inhibitor (PD98059) plus BEZ235, on five primary PDAC cell lines and on two pairs of parent and erlotinib-resistant (ER) cell lines. A range of in vitro assays including cell proliferation, Western blotting, migration, clonogenic, cell cycle, and apopotic assays was used to test for the efficacy of combined blockade. RESULTS: Dual downstream blockade of the MAPK and PAM pathways was more effective in attenuating downstream molecular signals. Synergy was demonstrated for erlotinib and BEZ235 and for PD-98059 and BEZ-235. This resulted in a trend of increased growth cell cycle arrest, apoptosis, cell proliferation, and colony and migration suppression. This combination showed more efficacy in cell lines with acquired resistance to erlotinib. CONCLUSIONS: The additional mTOR blockade provided by BEZ235 in combined blockade resulted in increased anticancer effect. The hypersensitivity of ER cell lines to additional mTOR blockade suggested PAM pathway oncogenic dependence via mTOR. Dual downstream combined blockade of MAPK and PAM pathways with MEK and PI3K/mTOR inhibitor appeared most effective and represents an attractive therapeutic strategy against pancreatic cancer and its associated drug resistance.http://www.sciencedirect.com/science/article/pii/S147655861630015X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthew H. Wong Aiqun Xue Robert C. Baxter Nick Pavlakis Ross C. Smith |
spellingShingle |
Matthew H. Wong Aiqun Xue Robert C. Baxter Nick Pavlakis Ross C. Smith Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma Neoplasia: An International Journal for Oncology Research |
author_facet |
Matthew H. Wong Aiqun Xue Robert C. Baxter Nick Pavlakis Ross C. Smith |
author_sort |
Matthew H. Wong |
title |
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
title_short |
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
title_full |
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
title_fullStr |
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed |
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
title_sort |
upstream and downstream co-inhibition of mitogen-activated protein kinase and pi3k/akt/mtor pathways in pancreatic ductal adenocarcinoma |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2016-07-01 |
description |
BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC). Our previous study suggested that epidermal growth factor receptor inhibitor erlotinib which acts upstream of these pathways acts synergistically with PI3K inhibitors in PDAC. Horizontal combined blockade upstream and downstream of these two pathways is therefore explored. METHODS: Erlotinib paired with PI3K inhibitor (BYL719) was tested against erlotinib plus dual PI3K/mTOR inhibitor BEZ-235, and MEK inhibitor (PD98059) plus BEZ235, on five primary PDAC cell lines and on two pairs of parent and erlotinib-resistant (ER) cell lines. A range of in vitro assays including cell proliferation, Western blotting, migration, clonogenic, cell cycle, and apopotic assays was used to test for the efficacy of combined blockade. RESULTS: Dual downstream blockade of the MAPK and PAM pathways was more effective in attenuating downstream molecular signals. Synergy was demonstrated for erlotinib and BEZ235 and for PD-98059 and BEZ-235. This resulted in a trend of increased growth cell cycle arrest, apoptosis, cell proliferation, and colony and migration suppression. This combination showed more efficacy in cell lines with acquired resistance to erlotinib. CONCLUSIONS: The additional mTOR blockade provided by BEZ235 in combined blockade resulted in increased anticancer effect. The hypersensitivity of ER cell lines to additional mTOR blockade suggested PAM pathway oncogenic dependence via mTOR. Dual downstream combined blockade of MAPK and PAM pathways with MEK and PI3K/mTOR inhibitor appeared most effective and represents an attractive therapeutic strategy against pancreatic cancer and its associated drug resistance. |
url |
http://www.sciencedirect.com/science/article/pii/S147655861630015X |
work_keys_str_mv |
AT matthewhwong upstreamanddownstreamcoinhibitionofmitogenactivatedproteinkinaseandpi3kaktmtorpathwaysinpancreaticductaladenocarcinoma AT aiqunxue upstreamanddownstreamcoinhibitionofmitogenactivatedproteinkinaseandpi3kaktmtorpathwaysinpancreaticductaladenocarcinoma AT robertcbaxter upstreamanddownstreamcoinhibitionofmitogenactivatedproteinkinaseandpi3kaktmtorpathwaysinpancreaticductaladenocarcinoma AT nickpavlakis upstreamanddownstreamcoinhibitionofmitogenactivatedproteinkinaseandpi3kaktmtorpathwaysinpancreaticductaladenocarcinoma AT rosscsmith upstreamanddownstreamcoinhibitionofmitogenactivatedproteinkinaseandpi3kaktmtorpathwaysinpancreaticductaladenocarcinoma |
_version_ |
1725484395656118272 |